Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THALASSA: ianalumab versus placebo in adults with Sjögren's disease and high symptom burden
2025-522271-29-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing ianalumab with placebo to ianalumab (2 arms). Primary endpoint: Change from baseline in SSSD oral dryness score at Week 52. Planned start Oct 2026; status: authorised.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2025-522271-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522271-29-00.